Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway

The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink Partners said “fell well below expectations.”